Leaflet IRETIG 50mg prolonged-release tablets

Indicated for: overactive bladder; urinary incontinence

Route of administration: oral

Substance: mirabegron (beta-3 adrenergic agonist)

ATC: G04BD12 (Genito urinary system and sex hormones | Urologicals | Drugs for urinary frequency and incontinence)

Mirabegrone is a medication used for the treatment of overactive bladder, characterized by symptoms such as frequent urination, urinary urgency, and urinary incontinence. It acts as a beta-3 adrenergic receptor agonist, relaxing the bladder muscles and increasing its capacity.

The medication is taken orally, usually once daily, and is effective in reducing symptoms associated with overactive bladder.

Side effects may include high blood pressure, urinary tract infections, headache, and nausea. It is important to monitor blood pressure during treatment.

Consult your doctor to discuss the benefits and risks of treatment with Mirabegrone. Follow the prescribed dosage and adhere to all medical recommendations.

General data about IRETIG 50mg

  • Substance: mirabegron
  • Date of latest medicines list: 01-12-2024
  • Product code: W70723001
  • Concentration: 50mg
  • Pharmaceutical form: prolonged-release tablets
  • Quantity: 30
  • Product type: Generic medicine
  • Prescription status: P-RF - Medicines dispensed with a medical prescription that is retained by the pharmacy and cannot be renewed.

Marketing authorisation

  • Manufacturer: PHARMADOX HEALTHCARE LTD. - MALTA
  • Holder: ZENTIVA, K.S. - REPUBLICA CEHA
  • Number: 15686/2024/01
  • Shelf life: 2 years

Concentrations available for mirabegron

  • 25mg
  • 50mg